Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Reprogrammed Mouse Fibroblasts Can Make A Whole Mouse
In a paper publishing online July 23 in Cell Stem Cell, a Cell Press journal, Dr. Shaorong Gao and colleagues from the National Institute of Biological Sciences in Beijing, China, report an important advance in the characterization of reprogrammed induced pluripotent stem cells, or iPSCs.
generic viagra online
Henry Ford Hospital Study May Hold Promise For Future Disease Therapies
Linking genetic material microRNAs with cells that regulate the immune system could one day lead to new therapies for treating cancer, infections and autoimmune diseases, according to a Henry Ford Hospital study.
News of the day
Pitt Researchers Find Promising Candidate Protein For Cancer Prevention Vaccines
Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers. The finding suggests that a vaccine against the protein might prevent malignancies in high-risk individuals.
Sexual Health

Cellceutix Files Patent Application For Its Cancer Compound

Cellceutix Corporation (OTCBB: CTIX), announced it has filed a U.S. patent application covering pharmaceutical formulations of a compound referred to as Kevetrin™ and many novel compounds having similar structures to Kevetrin. These structures cover a large number of compounds that Cellceutix can look at as possible drug development candidates. The application covers the use of Kevetrin™ and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing. George Evans, CEO stated: "This is a very exciting time for Cellceutix. The compounds covered by this patent application are structurally very different from anti-cancer agents currently on the market. Quite frankly, it took us longer than we expected to file this patent application due to the additional compounds that presented themselves as Kevetrin™ related structures. The result is a patent with new and expanded claims that will provide a strong intellectual property base for Kevetrin and a large portfolio of possible compounds for future development. In the meantime, we"ve been doing some very interesting experiments with Kevetrin and with our psoriasis candidate, KM-133. We anticipate announcing study results over the coming weeks." Cellceutix


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009